No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

BACKGROUND: The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependent on cytochrome P450 metabolism. We explored the potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Vangsted, Annette J, Søeby, Karen, Klausen, Tobias W, Abildgaard, Niels, Andersen, Niels F, Gimsing, Peter, Gregersen, Henrik, Vogel, Ulla, Werge, Thomas, Rasmussen, Henrik B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922196/
https://www.ncbi.nlm.nih.gov/pubmed/20684753
http://dx.doi.org/10.1186/1471-2407-10-404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922196/
https://www.ncbi.nlm.nih.gov/pubmed/20684753
http://dx.doi.org/10.1186/1471-2407-10-404

Ejemplares similares